Suppr超能文献

前一天淋巴闪烁显像后行前哨淋巴结活检的黑色素瘤患者报告的生存结果更差,这似乎并不是由于 Tc99m-纳米胶体示踪剂的夜间迁移所致。

The worse survival outcomes reported for melanoma patients having sentinel node biopsy after lymphoscintigraphy the previous day do not appear to be due to overnight migration of Tc99m-nanocolloid tracer.

机构信息

Department of Plastic Surgery, Herlev and Gentofte Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.

Department of Clinical Physiology, Nuclear Medicine and PET, Herlev and Gentofte Hospital, Copenhagen, Denmark.

出版信息

Eur J Surg Oncol. 2021 Sep;47(9):2450-2453. doi: 10.1016/j.ejso.2021.03.241. Epub 2021 Mar 17.

Abstract

INTRODUCTION

It has been reported that the survival of patients having sentinel node (SN) biopsy for melanoma the day after lymphoscintigraphy using Tc99m-nanocolloid is worse than that of patients having lymphoscintigraphy and SN biopsy on the same day [1,2]. A possible explanation suggested is that overnight migration of the tracer from SNs to 2nd-tier nodes occurs, causing failure to remove true SNs.

MATERIALS AND METHODS

The possibility of overnight tracer migration leading to errors in SN-identification was investigated in 12 patients scheduled for lymphoscintigraphy the day before surgery by repeating SPECT-CT imaging the next morning, before their SN biopsy. The aim was to check whether onward migration of colloid from previously-identified SNs had occurred.

RESULTS

No significant migration of Tc99m-nanocolloid occurred overnight in any patient. All nodes reported to be SNs on day 1 imaging were also present and regarded as SNs on day 2 images. No new foci were visualised on day 2, but some that had been identified on day 1 were not seen on day 2.

CONCLUSIONS

Since migration of nanocolloid overnight did not occur, this cannot explain the reported survival disadvantage for patients undergoing SN biopsy the day after lymphoscintigraphy. A likely alternative possibility is that inadequate doses of radioisotope were used for next-day procedures, causing the mistaken removal of 2nd-tier nodes instead of true SNs more frequently. Further research is required to explain the reported reduction in survival of patients having next-day SN biopsy procedures, since the possibility has important clinical implications.

摘要

简介

据报道,使用 Tc99m-纳米胶体进行淋巴闪烁显像后第二天进行前哨淋巴结 (SN) 活检的患者的生存率比同一天进行淋巴闪烁显像和 SN 活检的患者差[1,2]。提出的一个可能的解释是示踪剂从 SN 向二级节点的夜间迁移导致无法切除真正的 SN。

材料和方法

为了研究示踪剂的夜间迁移是否会导致 SN 识别错误,我们对 12 名计划在手术前一天进行淋巴闪烁显像的患者进行了研究,在进行 SN 活检前的第二天早上重复进行 SPECT-CT 成像。目的是检查胶体是否从先前识别的 SN 中发生了迁移。

结果

在任何患者中,Tc99m-纳米胶体都没有发生明显的夜间迁移。在第 1 天的图像中报告为 SN 的所有节点在第 2 天的图像中也存在并被视为 SN。第 2 天没有观察到新的焦点,但第 1 天已经识别的一些焦点在第 2 天没有观察到。

结论

由于纳米胶体没有发生夜间迁移,因此不能解释报告中进行 SN 活检的患者在淋巴闪烁显像后第二天生存率下降的原因。一个可能的替代可能性是,第二天的程序使用的放射性同位素剂量不足,导致经常错误地切除二级节点而不是真正的 SN。需要进一步的研究来解释报告中第二天进行 SN 活检程序的患者生存率降低的原因,因为这种可能性具有重要的临床意义。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验